Kamada Ltd (IL:KMDA)
NASDAQ:KMDA
KMDA Stock Chart & Stats
2523.00
1.39(5.72%)
At close: 4:00 PM EST
2523.00
1.39(5.72%)
Day’s Range― - ―
52-Week Range1,899.20 - 2,806.07
Previous CloseN/A
Volume698.59K
Average Volume (3M)75.27K
Market Cap
₪1.46B
Enterprise Value406.18M
Total Cash (Recent Filing)₪75.48M
Total Debt (Recent Filing)₪11.56M
Price to Earnings (P/E)20.7
Beta0.77
Next Earnings
May 26, 2026EPS Estimate
36.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)21.34
Shares Outstanding57,681,590
10 Day Avg. Volume53,307
30 Day Avg. Volume75,270
Financial Highlights & Ratios
PEG Ratio0.41
Price to Book (P/B)1.52
Price to Sales (P/S)2.09
P/FCF Ratio24.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₪4,392.67Price Target Upside74.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.51
Revenue Forecast (FY)₪201.58M
Bulls Say, Bears Say
Bulls Say
Commercial Portfolio ExpansionAnalyst notes that broader U.S. and international penetration of the commercial portfolio, supported by increased U.S. sales of VARIZIG and KEDRAB and ex-U.S. strength in KAMRAB and GLASSIA, should drive revenue growth.
Distribution And Biosimilar LaunchesAnalyst highlights that expansion of the Distribution segment and planned biosimilar launches provides a scalable, diversified revenue source beyond existing specialty products.
Plasma Collection And Vertical IntegrationAnalyst views the ramp of in-house plasma collection operations, including regulatory approval for the San Antonio site, as an underappreciated contributor to future revenue and margin improvement through lower specialty plasma input costs.
Bears Say
Capital Reallocation UncertaintyAnalyst raises uncertainty about how capital freed from the discontinued trial will be reallocated, which could delay investments needed to accelerate growth across the existing portfolio.
Clinical Trial DiscontinuationAnalyst notes that discontinuation of a key Phase 3 inhaled therapy trial creates uncertainty about the drug development pipeline and removes a potential future revenue catalyst.
Reduced Royalty RateAnalyst warns that a reduced GLASSIA royalty rate from a partner will lower product royalty income and could pressure revenue.
Kamada News
KMDA FAQ
What was Kamada Ltd’s price range in the past 12 months?
Kamada Ltd lowest stock price was 1899.20 and its highest was 2806.07 in the past 12 months.
What is Kamada Ltd’s market cap?
Kamada Ltd’s market cap is ₪1.46B.
When is Kamada Ltd’s upcoming earnings report date?
Kamada Ltd’s upcoming earnings report date is May 26, 2026 which is in 58 days.
How were Kamada Ltd’s earnings last quarter?
Kamada Ltd released its earnings results on Mar 11, 2026. The company reported 21.336 earnings per share for the quarter, missing the consensus estimate of 24.473 by -3.138.
Is Kamada Ltd overvalued?
According to Wall Street analysts Kamada Ltd’s price is currently Undervalued.
Does Kamada Ltd pay dividends?
Kamada Ltd pays a Notavailable dividend of 71.008 which represents an annual dividend yield of N/A. See more information on Kamada Ltd dividends here
What is Kamada Ltd’s EPS estimate?
Kamada Ltd’s EPS estimate is 36.08.
How many shares outstanding does Kamada Ltd have?
Kamada Ltd has 57,681,590 shares outstanding.
What happened to Kamada Ltd’s price movement after its last earnings report?
Kamada Ltd reported an EPS of 21.336 in its last earnings report, missing expectations of 24.473. Following the earnings report the stock price went down -5.059%.
Which hedge fund is a major shareholder of Kamada Ltd?
Currently, no hedge funds are holding shares in IL:KMDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kamada Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
₪4,392.67 (74.10% Upside)
₪4,392.67 (74.10% Upside)
Blogger Sentiment
Bullish
IL:KMDA Sentiment 70%
Sector Average 69%
Sector Average 69%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.94%
12-Months-Change
Fundamentals
Return on Equity
7.75%
Trailing 12-Months
Asset Growth
1.73%
Trailing 12-Months
Company Description
Kamada Ltd
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
KMDA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook with strong revenue growth, increased EBITDA, and successful product launches. However, challenges remain with declining Glacia royalties, below-plan Cytogam sales, and slow clinical trial enrollment.View all IL:KMDA earnings summariesKMDA Stock 12 Month Forecast
Average Price Target
4,392.67
▲(74.10% Upside)